Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07585630

A1Cantus vs. Placebo

The investigators will conduct a randomized controlled 2-arm parallel trial of A1c Drink vs. Placebo over a 3-month period and compare changes in Ha1c from baseline to 3 months. Investigator and study personnel, as well as participants, will be blinded to drink assignments.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Type 2 Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

21 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults 21 years of age or older and not older than 75 recruited from UCR Health
  • Clinical diagnosis of type II DM with Ha1c >= 8 but less than or equal to 10
  • Stable medications for at least 6 months
  • Speak Spanish and/or English
  • Sign an informed consent form
  • No other members in their household are participating in the study

Exclusion criteria

  • Patients <21 years of age, who do not have type II DM, whose Ha1c is less than 8 or > 10,
  • Have major complications of diabetes, including CKD, diabetic retinopathy, ADVD risk > 5, or history of CVD/stroke
  • Do not speak and understand either English or Spanish well
  • Allergic to cinnamon
  • Severe diseases, such as cancer
  • Compromised immune system
  • Eating disorders
  • BMI of 40 or higher
  • Already have a family member participating in the study
  • Substance use disorder

Treatment and study plan

A1C Drink

Dietary Supplement

In the experimental arm, participants will drink the A1C drink BID for 3 months as instructed. Both the active and placebo drinks will be identical in can size (12 oz slim can), packaging format, and visual appearance.

Placebo drink

Other

In the placebo arm, participants will drink the placebo drink BID for 3 months as instructed. Both the active and placebo drinks will be identical in can size (12 oz slim can), packaging format, and visual appearance.

Primary outcomes

  1. Hemoglobin A1C

    Time frame: 3 months

    Change in Ha1c from baseline to 3 months. To test the efficacy of the A1Cantus drink in improving glycemic control in patients with Type II Diabetes

Secondary outcomes

  1. Change in A1C

    Time frame: 3 months

    Percentage of participants whose A1C was lowered from Baseline to 3 months

  2. Hypertension

    Time frame: 3 months

    Change in systolic and diastolic blood pressure from baseline to three months

  3. Body Mass Index (BMI)

    Time frame: 3 months

    Change in body mass index from baseline to 3 months

  4. Cholesterol

    Time frame: 3 months

    Change in fasting LDL and HDL from baseline to three months

Study contacts

Contact information is provided by the study sponsor or research team.

Elizabeth Jacobs, MD, MPP

CONTACT

[email protected]

951-827-8643

Sponsors and collaborators

Lead sponsor

University of California, Riverside

Other

Collaborators

  • A1Cantus

Registry information

Official study title

Double-Blind Randomized Controlled Trial of A1Cantus Drink vs. Placebo for Reduction of Ha1c

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
May 14, 2026
Registry last updated
May 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.